Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Steven H. Lin, MD
CONTACT
Lead
M.D. Anderson Cancer Center
With
Primary Objectives: 1. Estimate the level of lymphocyte restoration after administration of NKTR-255 concurrently with durvalumab after chemoradiation. Absolute lymphocyte will be obtained along with changes in levels of NK cells, CD4 T cells, CD8 T cells, and B cells from baseline. 2. Monitor the safety of NKTR-255, which includes treatment related grade 3+ radiation pneumonitis Secondary Objectives: 1. Estimate the Progression-free survival time distribution 2. Estimate the Overall survival time distribution Exploratory objectives: 1. Characterize pharmacokinetics of NKTR-255 and assess immunogenicity of NKTR-255 2. Characterize pharmacodynamic effects and changes in activation markers and proliferation of NK and CD8 T cells, and cytokine levels after administration of NKTR-255 in combination with Durvalumab 3. Assess the correlation between ctDNA and efficacy measurements
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
